Celator Pharmaceuticals Inc., of Ewing, N.J., said independent data and safety monitoring board for the company’s Phase III study comparing CPX-351 (cytarabine/daunorubicin) liposome injection to the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia should continue as planned without any modifications.